ACTU
What one share of Actuate Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”).
Actuate Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.89 |
|---|---|
| Cash and investments | $0.18 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$17.24 | — | −$15.07 | — | −$58.92 |
| 2024 | — | −$3.26 | — | −$2.61 | — | — |
| 2025 | — | −$1.06 | — | −$0.91 | — | $0.34 |